High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
The development of reliable biomarkers for the prediction of immune checkpoint inhibition (ICI) response in patients with metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) remains an unresolved challenge. Conventional ICI biomarkers typically focus on tumor-related factors such as PD-L1 expression. However, a comprehensive evaluation of the predictive value of serum electrolyte levels, a so far widely unexplored area, is still pending.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: KlumperNiklas Kl ümper, Alexander Cox, Markus Eckstein, Christoph Kuppe, Manuel Ritter, Peter Brossart, Julian Luetkens, HolzelMichael Hölzel, Johannes Stein, Jonas Saal Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Sodium